Background: The value of radiation therapy (RT) and hormonal therapy (HT) in stage Dl prostatic cancer was to date only sporadically compared with radical prostatectomy (RP) and hormonal therapy Patients and Methods: From 1975 to 1991, 82 patients with pelvic lymph node dissection (PLND)-proven stage Dl prostatic carcinoma underwent RT. Twelve patients were excluded from analysis because treatment started when local tumor progression was observed. Of the remaining 70 patients 30 initially had an RP with orchiectomy and 40 patients had only a biopsy with orchiectomy. All patients had an additional androgen blocking. Fifty-five out of 70 patients were treated with photons up to a total dose of 4,000-5,000 cGy to the pelvic lymphatics and an additional boost to the prostatic region to deliver 6,000-7,000 cGy. In 12 out of 67 patients 14-MeV fast neutrons were used for the boost. Three patients had only a local RT. Results: The median follow-up in 30 patients with RP, designated as group I, was 54 months and in 40 patients with biopsy only, designated as group II, was 58 months. The 5- and 10-year overall survival (OS) rates were 90 and 53% in group I compared to 72 and 41% in group II, respectively (p > 0.05). The cause-specific survival (CSS) for 5 and 10 years was 100 and 58% versus 79 and 72% (p > 0.05). Disease-free survival (DFS) for 5 and 10 years was 70% in group I and 65 and 24% in group II, respectively (p > 0.05). Local control (LC) for 5 and 10 years was 87% (group I) versus 94% (group II) and 87% (group I) versus 65% (group II) (p > 0.05). Major complications occurred in 6% (4 patients); all of these were treated following RP. Conclusions: In the present series no significant advantage was seen for patients treated with RP, RT and HT, compared to RT and HT. RT in combination with immediate HT seems to be able to achieve results comparable with those of RP when using immediate HT. This should be proven in prospective clinical trials.

Keywords:
Prostatic carcinoma, Radiotherapy, Stage Dl prostatic cancer
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.